What Versican Plus Pi/L4R Treats: Main Uses and Benefits

The primary function of Versican Plus Pi/L4R is to provide preventative support against five distinct infectious agents, including the Rabies virus, Canine Parainfluenza Type 2 virus, and four Leptospira serovars (Icterohaemorrhagiae, Canicola, Grippotyphosa, Australis). This preventative action is relevant for managing health risks and supports the animal's long-term comfort and stability.

The product is commonly used in situations involving the prevention of severe systemic and neurological disease and common contagious respiratory illness. These conditions are characterized by severe outcomes, including acute neurological collapse and systemic organ damage. The product is relevant in conditions involving Rabies, Leptospirosis, and Parainfluenza.

The preventative support may help reduce the severity of potential health crises. This comprehensive measure may assist with long-term preventative health management and is relevant for reducing community risk, which supports general well-being during symptomatic phases.

Quick Fact: Prevention of Infectious Manifestations
Supports the dog's defense system in high-risk scenarios, contributing to the management of severe systemic outcomes and neurological symptoms, and helping to prevent persistent respiratory discomfort.

Regulatory References

1. European Medicines Agency product information

This section outlines the official eligibility criteria for Versican Plus Pi/L4R, based strictly on governmental regulatory documents such as the Summary of Product Characteristics (SmPC).

Eligible Population

Versican Plus Pi/L4R is intended for the active immunization of healthy dogs and puppies from 8–9 weeks of age. Vaccination requires a fully competent immune system. Therefore, animals whose immune status may be compromised by factors like poor health, nutritional deficiencies, or concurrent drug therapy are generally not considered suitable candidates for vaccination.

Contraindications and Restrictions

The regulatory documents state that there are no formal contraindications for this product. However, its use is strictly restricted or prohibited in specific circumstances:

• Rabies Suspects: The product must not be used in animals that are showing signs of rabies or are suspected of being infected with rabies virus.

• Pregnancy and Lactation: Use is not recommended during the early stage of pregnancy and throughout lactation, as the safety of the product has not been fully established during these periods. The vaccine can be used during the second and third stages of pregnancy.

Interactions with other medicines and products

Official regulatory documentation defines the interaction profile of Versican Plus Pi/L4R, a veterinary immunological product, based primarily on its biological function related to active immunisation. This profile is structured around the risk of pharmacodynamic interference that may compromise the expected biological response.

---

Documented Interaction Restrictions

The primary concern documented in regulatory labeling involves substances that affect the immune system.

Interaction Type	Interacting Substance/Class	Official Regulatory Restriction
Pharmacodynamic	Immunosuppressive medicinal products	Co-administration may result in an impaired immune response due to counteraction of the vaccine’s intended action.
Co-administration Rule	Immunosuppressive medicinal products	Must not be administered simultaneously (Prohibited co-administration) to prevent reduced vaccine efficacy.

The restriction is based on the necessity for the dog's immune system to be fully functional to develop protective defenses against the contained antigens. Therefore, agents such as corticosteroids at immunosuppressive doses fall under this prohibition to avoid reducing the vaccine’s efficacy.

Absence of Documented Interactions

Official regulatory labeling does not contain specific documentation detailing interactions with other substance categories. There are no official statements regarding pharmacokinetic interactions, such as those involving metabolic enzymes or drug transporters. Furthermore, there are no documented restrictions concerning interactions with food, alcohol, herbal products, or dietary supplements. The regulatory documents do not specify any timing-based separation rules with non-immunosuppressive medicines.

Versican Plus Pi/L4R is a multivalent veterinary biologic targeting multiple specific viral and bacterial antigens. The mechanism of action is active immunization, involving the administration of antigens to specialized host cells, primarily in the lymphoid tissues at the subcutaneous injection site.

Viral and Bacterial Component Interaction

The vaccine contains live attenuated Canine Parainfluenza Virus (CPiV) Type 2 and inactivated antigens from four Leptospira serovars (Icterohaemorrhagiae, Canicola, Grippotyphosa, Bratislava), along with inactivated Rabies Virus antigen. The inactivated components utilize an aluminum hydroxide adjuvant to potentiate the immune response by promoting antigen presentation and local cytokine/chemokine release within the injection microenvironment, recruiting antigen-presenting cells (APCs).

Molecular and Cellular Cascade

APCs, such as dendritic cells, internalize the viral and bacterial antigens. These antigens are processed into epitopes and presented on Major Histocompatibility Complex (MHC) molecules, activating naïve T-lymphocytes via the T-cell receptor (TCR) binding interaction. B-lymphocytes are simultaneously engaged and undergo clonal expansion and differentiation into plasma cells following T-cell dependent B-cell activation.

Downstream and System-Level Consequences

The downstream cascade results in the systemic production of pathogen-specific antibodies (humoral immunity) and the proliferation of cytotoxic T-lymphocytes (cellular immunity) against CPiV and Rabies virus (primarily). Crucially, immunological memory is established through the development of long-lived memory B-cells and T-cells capable of a rapid and amplified secondary immune response upon subsequent encounter with the specified native pathogens.

Official Administration Instructions

Versican Plus Pi/L4R is administered as a single dose of the reconstituted product via the subcutaneous route (under the skin). The product must only be used in healthy animals.

Preparation and Dosing

1. Reconstitution: The lyophilisate (freeze-dried pellet) must be aseptically reconstituted with the entire volume of the suspension component. This should be done immediately prior to injection.
2. Mixing: The reconstituted product must be shaken well.
3. Administration: The entire content of the mixed product, 1 mL, is administered as a single dose. The resulting solution should appear pink/red or yellowish with slight opalescence. The product must not be mixed with any other veterinary medicinal products.

Dosing Schedule

Vaccination Type	Age/Timing	Dose Volume/Frequency
Primary Course (First Dose)	From 8–9 weeks of age	1 mL single dose
Primary Course (Second Dose)	3–4 weeks after the first dose, and not before 12 weeks of age	1 mL single dose
Re-vaccination (Rabies component)	Every 3 years	1 mL single dose
Re-vaccination (Parainfluenza and Leptospira components)	Annually (every year)	A single dose of a compatible vaccine is required annually

The product can be used during the second and third stages of pregnancy.

Research Evidence / Overview of Studies for Versican Plus Pi/L4R

Evidence for Use in Rabies Prevention

Research into the Rabies component of Versican Plus Pi/L4R was studied for immunological measurements. The evidence base includes controlled laboratory challenge studies which explored outcomes related to mortality and clinical signs following exposure to the Rabies virus. Additionally, field immunogenicity studies were observed in to monitor patterns in the development of specific antibody levels, or seroconversion, in the animal populations studied. These studies specifically monitored outcomes related to mortality and clinical signs and assessed the presence of specific antibody levels.

Findings describe patterns observed in these studies, with measurements data show patterns related to the presence of antibodies for at least three years after the initial primary course of administration. The non-achievement of the required antibody level in a minority of healthy dogs was observed in some studies during the immediate three-to-four-week period following a single primary vaccination dose. Existing data provides limited information for long-term outcomes that might extend beyond the reported three-year mark.

---

Evidence for Use in Canine Parainfluenza Virus (CPiV) Prevention

Research examined whether there was a prevention or reduction of clinical signs associated with CPiV and research monitored viral excretion (shedding) levels. Studies monitored outcomes related to the prevention or absence of clinical respiratory signs and viral excretion (shedding) levels in research subjects exposed to the virus. Measurements supporting a duration of antibody presence of at least one year were reported.

---

Evidence for Use in Leptospirosis Prevention (L4 Serovars)

The evidence base for the four Leptospira serovars is built primarily upon controlled laboratory challenge studies. The studies monitored outcomes related to the prevention or reduction of clinical disease symptoms, systemic infection, and bacterial urine (urinary shedding) levels. Immunological findings data show patterns related to the duration of antibody presence for at least one year.

A primary area of uncertainty lies in the variability of findings across the four Leptospira serovars. Published research has noted limitations in consistently monitoring systemic infection levels for Icterohaemorrhagiae in certain comparative challenge models. There is limited information for long-term outcomes extending beyond the one-year study interval.

---

Research Gaps and Areas of Uncertainty

The research conducted so far contributes to the overall evidence base, but there are areas where certainty remains low or where data are still emerging. Key limitations include the variability in reported outcomes for the Leptospira serovars and the limited one-year follow-up for the CPiV and Leptospira components. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Annex I: Summary of Product Characteristics (SPC) - Versican Plus Pi/L4R

Common questions about Versican Plus Pi/L4R (FAQ)

Q: What is the onset of immunity for the Canine Parainfluenza Virus (CPiV) component?

Studies described in official regulatory documents indicate that the onset of immunity for the Canine Parainfluenza Virus (CPiV) component is typically achieved three weeks after the primary vaccination course is completed.

---

Q: Is the vaccine component for CPiV a 'live attenuated' strain?

Yes, the Canine Parainfluenza Virus component is a live attenuated strain. This means the virus has been modified, or 'attenuated,' in a laboratory to stimulate the immune system, according to the official product composition.

---

Q: Does the rabies component provide enough antibody titer for international travel requirements?

Regulatory information indicates that the rabies component is proven effective following a single dose from 12 weeks of age in lab studies. However, official warnings note that some dogs in field studies may not immediately meet the antibody titre of 0.5 IU/mL required by certain non-EU countries for travel. If international travel is planned, verifying the dog's rabies antibody level and the specific destination's requirements with a veterinarian is often necessary, as some regions may require additional measures.

---

Q: Why are there different efficacy results reported between 'laboratory' and 'field' studies for the rabies component?

Official reports highlight that while laboratory studies confirm the efficacy of the rabies fraction, field studies show variability. Regulatory warnings indicate this difference, noting that field studies inherently incorporate a wider range of environmental and genetic factors than the controlled laboratory setting.

---

Q: What should I do if I accidentally inject myself with the vaccine?

Official safety precautions state that if accidental self-injection occurs, the regulatory requirement is to seek medical advice immediately and show the package leaflet or label to the medical professional.

---

Q: What does the TCID50 measurement mean on the label?

The TCID50 (Tissue Culture Infectious Dose 50%) is a measurement used in the product information to quantify the amount of the live attenuated virus component (like CPiV) present in each dose. This figure represents the concentration of virus required to infect 50% of the tissue cultures in a laboratory test.

---

Q: What happens if a dog receives more than the recommended dose (overdose)?

Official overdose studies indicate that no adverse reactions beyond those listed as common or rare were observed after administering a dose up to 10 times the recommended amount. In a minority of animals, transient pain was observed at the injection site immediately after the overdose; this reaction subsided without needing therapy, according to regulatory data.

---

Q: Does the presence of maternally-derived antibodies in puppies interfere with this vaccine?

Official documentation mentions that maternally-derived antibodies (MDA)—those passed from the mother to the puppy—can sometimes cause a delayed immune response to some viral components. However, the vaccine has been shown in studies to still be protective against viral challenge, even with MDA present. The official protocol requires the veterinarian to manage the vaccination timing based on expected maternally-derived antibody levels in the puppy.

---

Q: What is the risk of my vaccinated dog 'shedding' the virus to unvaccinated dogs?

The official product information confirms that the live attenuated CPiV strain may be shed by vaccinated dogs. Regulatory documents indicate that due to the low pathogenicity of this strain, separation of vaccinated and non-vaccinated dogs is generally not required.

---

Q: Will the vaccine still work if it accidentally freezes?

Official storage instructions are strict: the product must be stored and transported refrigerated at 2 C to 8 C. The regulatory documents explicitly state that the product must not freeze.

---

Q: Can the vaccine be co-administered with non-immunosuppressive medicines?

Regulatory documents restrict co-administration only with immunosuppressive medicines. For all other non-immunosuppressive medicines, the official product information states no specific safety or efficacy information is available regarding simultaneous use. Official guidance states that a decision regarding the use of this vaccine before or after any other non-immunosuppressive veterinary medicinal product should be made by the veterinarian on a case-by-case basis.

---

Q: What is the regulatory difference between 'prevention of clinical signs' and 'reduction of viral excretion'?

The official indications differentiate these outcomes. Prevention of clinical signs refers to preventing the visible symptoms of illness (like coughing or lethargy). Reduction of viral excretion refers to minimizing the amount of virus the animal sheds into the environment, which is important for limiting the spread of infection to other animals.

Storage and Disposal of Versican Plus Pi/L4R

Official Storage Requirements

Versican Plus Pi/L4R must be stored and transported refrigerated at a temperature range of 2, C to 8, C. The product must not freeze and must be protected from light. For safety, the medicine must be kept out of the sight and reach of children.

Stability and Handling

The shelf life of the unopened product is 2 years. Once the lyophilisate is reconstituted with the solvent, the resulting vaccine suspension must be used immediately.

Disposal Instructions

Unused product or waste materials derived from it must be disposed of in accordance with local requirements. Medicines must not be disposed of via wastewater or household waste; instead, approved take-back schemes should be utilized.